Rachel E. Sanborn

机构：Cancer Institute (WIA), Providence Portland Medical Center · ORCID：0000-0003-0542-6054

发表论文 300 篇 · 总被引 9511 次 · h-index 39

代表论文

• Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non–Small Cell Lung Cancer (2025 · Journal of Clinical Oncology · 被引 8)
• 2758MO Updated results from a phase I/II study of gocatamig for small cell lung cancer (SCLC) and other neuroendocrine cancers (2025 · Annals of Oncology · 被引 6)
• Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer (2025 · British Journal of Cancer · 被引 2)
• First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6–Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non–Small Cell Lung Cancer (2026 · Journal of Clinical Oncology · 被引 1)
• Identification of a TCR to a non-canonical peptide (NCP) presented by the autologous non-small cell lung cancer (NSCLC) following an immunotherapy that includes canonical and NCPs 3338 (2025 · The Journal of Immunology · 被引 1)
• Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC (2025 · Lung Cancer · 被引 1)